(Q39621823)

13 September 2017

title

Personalised medicine in oncology: questions for the next 20 years (English)

1 reference

13 September 2017

1

1 reference

13 September 2017

Denis Lacombe

2

1 reference

13 September 2017

Françoise Meunier

series ordinal

3

1 reference

13 September 2017

Roger Stupp

series ordinal

4

1 reference

13 September 2017

publication date

1 May 2012

1 reference

Lancet Oncology Commission

13 September 2017

published in

1 reference

13 September 2017

volume

13

1 reference

13 September 2017

issue

5

1 reference

13 September 2017

page(s)

448-449

1 reference

Complex landscapes of somatic rearrangement in human breast cancer genomes

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970156-0

7 January 2021

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970156-0

7 January 2021

Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970156-0

7 January 2021

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970156-0

7 January 2021

A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970156-0

7 January 2021

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970156-0

7 January 2021

HER2 status and benefit from adjuvant trastuzumab in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970156-0

7 January 2021

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970156-0

7 January 2021

10.1016/S1470-2045(12)70156-0

Identifiers

DOI

1 reference

13 September 2017

1 reference